Last reviewed · How we verify
labetalol intravenous
Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking sympathetic nervous system signaling.
Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking sympathetic nervous system signaling. Used for Acute hypertension, Hypertensive emergency, Perioperative hypertension.
At a glance
| Generic name | labetalol intravenous |
|---|---|
| Sponsor | Haseki Training and Research Hospital |
| Drug class | Alpha-beta adrenergic antagonist |
| Target | Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Labetalol acts as a non-selective beta-blocker with concurrent alpha-1 adrenergic blocking activity, resulting in vasodilation and reduced cardiac output. The intravenous formulation provides rapid onset of action, making it suitable for acute hypertensive episodes. The dual mechanism produces effective blood pressure reduction with a favorable hemodynamic profile compared to pure beta-blockers.
Approved indications
- Acute hypertension
- Hypertensive emergency
- Perioperative hypertension
Common side effects
- Dizziness
- Fatigue
- Nausea
- Tremor
- Headache
- Hypotension
Key clinical trials
- A Comparison of Nicardipine and Labetalol for Blood Pressure Control in Intensive Care Patients After Hemorrhagic Stroke Brain Surgery (NA)
- Nicardipine vs. Labetalol (PHASE4)
- Comparative Efficacy of Intravenous Labetalol and Lignocaine in Mitigating Hemodynamic Responses to Laryngoscopy During Laparoscopic Cholecystectomy (NA)
- Postpartum Hypertension Study (PHASE4)
- Intravenous Labetalol Versus Hydralazine in Preeclampsia (PHASE1, PHASE2)
- The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II (PHASE2)
- Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia. (NA)
- Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- labetalol intravenous CI brief — competitive landscape report
- labetalol intravenous updates RSS · CI watch RSS
- Haseki Training and Research Hospital portfolio CI